Unconfirmed reports this week suggested the French drugmaker Sanofi had decided to sell the Kansas City plant and hired a commercial real estate agent to help it find a buyer.
A Sanofi spokeswoman confirmed the report, telling in-Pharmatechnologist.com that plan is to sell “both the equipment and the site itself.”
She also confirmed that the facility produces the allergy treatment Allegra (Fexofenadine) and a number of other pharmaceutical products.
The site has been earmarked for closure since 2009 when Sanofi said that falling demand for the drug made continued operation of the facility economically unviable.
Since then Sanofi has been gradually laying of the 390 staff employees at the site and reducing manufacturing levels.
According to an official statement emailed to this publication “all manufacturing will cease by August 2016, and we intend to sell both the building and manufacturing equipment.”